Glauce Regina Pigatto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Glauce Regina Pigatto has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Alexandre Gomes de Macedo Maganin
Center for Research in Inflammatory Diseases (CRID), Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil
7 shared publications - Andreza Urba Quadros
Center for Research in Inflammatory Diseases (CRID), Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil
7 shared publications - Atlante S. Mendes
Center for Research in Inflammatory Diseases (CRID), Department of Pharmacology and
7 shared publications - Beatriz Adjafre
Superior Institute of Biomedical Sciences State University of Ceará Fortaleza Brazil
7 shared publications - Camila Meirelles de Souza Silva
Harvard Medical School
7 shared publications - Carlos Wagner de Souza Wanderley
Center of Research in Inflammatory Diseases (CRID) University of São Paulo Ribeirão Preto Brazil
7 shared publications
Latest Publications
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling
Supplementary Figure from PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling
Supplementary Figure from PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling
Supplementary Data from PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling
Supplementary Data from PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling
Supplementary Data from PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling
Supplementary Data from PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling
Cytotoxic agents synergize with immune checkpoint inhibitors and improve outcomes for patients with several cancer types. Nonetheless, a parallel increase in the incidence of dose-limiting side effects, such as peripheral neuropathy, is often observed. Here, we investigated the role of the programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) axis in the modulation of paclitaxel-induced neuropathic pain. We found that human and mouse neural tissues, including the dorsal root ganglion (DRG), expressed basal levels of PD-1 and PD-L1. During the development of paclitaxel-induced neuropathy, an increase in PD-L1 expression was observed in macrophages from the DRG. This effect depended on Toll-like receptor 4 activation by paclitaxel. Furthermore, PD-L1 inhibited pain behavior triggered by paclitaxel or formalin in mice, suggesting that PD-1/PD-L1 signaling attenuates peripheral neuropathy development. Consistent with this, we observed that the combined use of anti–PD-L1 plus paclitaxel increased mechanical allodynia and chronic neuropathy development induced by single agents. This effect was associated with higher expression of inflammatory markers (Tnf, Il6, and Cx3cr1) in peripheral nervous tissue. Together, these results suggest that PD-1/PD-L1 inhibitors enhance paclitaxel-induced neuropathic pain by suppressing PD-1/PD-L1 antinociceptive signaling.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling
Cytotoxic agents synergize with immune checkpoint inhibitors and improve outcomes for patients with several cancer types. Nonetheless, a parallel increase in the incidence of dose-limiting side effects, such as peripheral neuropathy, is often observed. Here, we investigated the role of the programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) axis in the modulation of paclitaxel-induced neuropathic pain. We found that human and mouse neural tissues, including the dorsal root ganglion (DRG), expressed basal levels of PD-1 and PD-L1. During the development of paclitaxel-induced neuropathy, an increase in PD-L1 expression was observed in macrophages from the DRG. This effect depended on Toll-like receptor 4 activation by paclitaxel. Furthermore, PD-L1 inhibited pain behavior triggered by paclitaxel or formalin in mice, suggesting that PD-1/PD-L1 signaling attenuates peripheral neuropathy development. Consistent with this, we observed that the combined use of anti–PD-L1 plus paclitaxel increased mechanical allodynia and chronic neuropathy development induced by single agents. This effect was associated with higher expression of inflammatory markers (Tnf, Il6, and Cx3cr1) in peripheral nervous tissue. Together, these results suggest that PD-1/PD-L1 inhibitors enhance paclitaxel-induced neuropathic pain by suppressing PD-1/PD-L1 antinociceptive signaling.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling
Cytotoxic agents synergize with immune checkpoint inhibitors and improve outcomes for patients with several cancer types. Nonetheless, a parallel increase in the incidence of dose-limiting side effects, such as peripheral neuropathy, is often observed. Here, we investigated the role of the programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) axis in the modulation of paclitaxel-induced neuropathic pain. We found that human and mouse neural tissues, including the dorsal root ganglion (DRG), expressed basal levels of PD-1 and PD-L1. During the development of paclitaxel-induced neuropathy, an increase in PD-L1 expression was observed in macrophages from the DRG. This effect depended on Toll-like receptor 4 activation by paclitaxel. Furthermore, PD-L1 inhibited pain behavior triggered by paclitaxel or formalin in mice, suggesting that PD-1/PD-L1 signaling attenuates peripheral neuropathy development. Consistent with this, we observed that the combined use of anti–PD-L1 plus paclitaxel increased mechanical allodynia and chronic neuropathy development induced by single agents. This effect was associated with higher expression of inflammatory markers (Tnf, Il6, and Cx3cr1) in peripheral nervous tissue. Together, these results suggest that PD-1/PD-L1 inhibitors enhance paclitaxel-induced neuropathic pain by suppressing PD-1/PD-L1 antinociceptive signaling.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling
Cytotoxic agents synergize with immune checkpoint inhibitors and improve outcomes for patients with several cancer types. Nonetheless, a parallel increase in the incidence of dose-limiting side effects, such as peripheral neuropathy, is often observed. Here, we investigated the role of the programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) axis in the modulation of paclitaxel-induced neuropathic pain. We found that human and mouse neural tissues, including the dorsal root ganglion (DRG), expressed basal levels of PD-1 and PD-L1. During the development of paclitaxel-induced neuropathy, an increase in PD-L1 expression was observed in macrophages from the DRG. This effect depended on Toll-like receptor 4 activation by paclitaxel. Furthermore, PD-L1 inhibited pain behavior triggered by paclitaxel or formalin in mice, suggesting that PD-1/PD-L1 signaling attenuates peripheral neuropathy development. Consistent with this, we observed that the combined use of anti–PD-L1 plus paclitaxel increased mechanical allodynia and chronic neuropathy development induced by single agents. This effect was associated with higher expression of inflammatory markers (Tnf, Il6, and Cx3cr1) in peripheral nervous tissue. Together, these results suggest that PD-1/PD-L1 inhibitors enhance paclitaxel-induced neuropathic pain by suppressing PD-1/PD-L1 antinociceptive signaling.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling
Supplementary Figure from PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling
Supplementary Figure from PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling
- 9 September 2022
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 10 (11) , 1299-1308
PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling
Cytotoxic agents synergize with immune checkpoint inhibitors and improve outcomes for patients with several cancer types. Nonetheless, a parallel increase in the incidence of dose-limiting side effects, such as peripheral neuropathy, is often observed. Here, we investigated the role of the programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) axis in the modulation of paclitaxel-induced neuropathic pain. We found that human and mouse neural tissues, including the dorsal root ganglion (DRG), expressed basal levels of PD-1 and PD-L1. During the development of paclitaxel-induced neuropathy, an increase in PD-L1 expression was observed in macrophages from the DRG. This effect depended on Toll-like receptor 4 activation by paclitaxel. Furthermore, PD-L1 inhibited pain behavior triggered by paclitaxel or formalin in mice, suggesting that PD-1/PD-L1 signaling attenuates peripheral neuropathy development. Consistent with this, we observed that the combined use of anti–PD-L1 plus paclitaxel increased mechanical allodynia and chronic neuropathy development induced by single agents. This effect was associated with higher expression of inflammatory markers (Tnf, Il6, and Cx3cr1) in peripheral nervous tissue. Together, these results suggest that PD-1/PD-L1 inhibitors enhance paclitaxel-induced neuropathic pain by suppressing PD-1/PD-L1 antinociceptive signaling.
- 9 September 2022
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 10 (11) , 1299-1308
PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling
Cytotoxic agents synergize with immune checkpoint inhibitors and improve outcomes for patients with several cancer types. Nonetheless, a parallel increase in the incidence of dose-limiting side effects, such as peripheral neuropathy, is often observed. Here, we investigated the role of the programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) axis in the modulation of paclitaxel-induced neuropathic pain. We found that human and mouse neural tissues, including the dorsal root ganglion (DRG), expressed basal levels of PD-1 and PD-L1. During the development of paclitaxel-induced neuropathy, an increase in PD-L1 expression was observed in macrophages from the DRG. This effect depended on Toll-like receptor 4 activation by paclitaxel. Furthermore, PD-L1 inhibited pain behavior triggered by paclitaxel or formalin in mice, suggesting that PD-1/PD-L1 signaling attenuates peripheral neuropathy development. Consistent with this, we observed that the combined use of anti–PD-L1 plus paclitaxel increased mechanical allodynia and chronic neuropathy development induced by single agents. This effect was associated with higher expression of inflammatory markers (Tnf, Il6, and Cx3cr1) in peripheral nervous tissue. Together, these results suggest that PD-1/PD-L1 inhibitors enhance paclitaxel-induced neuropathic pain by suppressing PD-1/PD-L1 antinociceptive signaling.
- Open Access
- 10 December 2020
- Published by Research, Society and Development in Research, Society and Development
- Vol. 9 (12)
Características demográficas e clínicas de portadores de migrânea
A migrânea é uma condição clínica referida como uma perturbação cefalálgica primária, comum e incapacitante, de alta prevalência e que produz impactos socioeconômicos e pessoais elevados. Ela possui manifestações episódicas, com crises recorrentes de cefaleia, apresentando-se com quadro de dor unilateral, pulsátil, de intensidade moderada ou severa. Por ser considerada uma afecção bastante comum e incapacitante, o objetivo desse estudo foi o de caracterizar, demográfica e clinicamente, portadores de migrânea. Esse trabalho faz parte de um estudo clínico duplo-cego, cruzado e randomizado sobre a aplicação de um tratamento com fotobiomodulação em portadores de migrânea. Quarenta e três indivíduos elegíveis, de ambos os gêneros, após uma triagem inicial e uma avaliação com neurologistas, foram randomizados (1:1) e separados no Grupo A e B e preencheram o Questionário de Avaliação da Incapacidade por Enxaqueca (MIDAS), o 12 – Item Allodynia Symptom Checklist (ASC – 12) – Versão Brasileira, e o Diário de Dor (durante um mês). Os resultados da caracterização da amostra mostraram maior ocorrência da migrânea nas mulheres, com homogeneidade em relação à idade, peso, altura, tempo de ocorrência, frequência e intensidade de dor entre os grupos. A náusea, fotofobia, fonofobia e osmofobia foram os fatores predisponentes mais evidentes nas análises realizadas. O MIDAS indicou presença de grau moderado de dor de cabeça em ambos os grupos e o ASC-12 do grupo A indicou presença de alodínia severa e no B, alodínia moderada. Esses dados indicam que a migrânea gera sérios problemas aos seus portadores, os quais interferem consideravelmente na sua qualidade de vida.
- 10 December 2020
- Published by Research, Society and Development in Research, Society and Development
- Vol. 9 (12)
Open AccessCaracterísticas demográficas e clínicas de portadores de migrânea
A migrânea é uma condição clínica referida como uma perturbação cefalálgica primária, comum e incapacitante, de alta prevalência e que produz impactos socioeconômicos e pessoais elevados. Ela possui manifestações episódicas, com crises recorrentes de cefaleia, apresentando-se com quadro de dor unilateral, pulsátil, de intensidade moderada ou severa. Por ser considerada uma afecção bastante comum e incapacitante, o objetivo desse estudo foi o de caracterizar, demográfica e clinicamente, portadores de migrânea. Esse trabalho faz parte de um estudo clínico duplo-cego, cruzado e randomizado sobre a aplicação de um tratamento com fotobiomodulação em portadores de migrânea. Quarenta e três indivíduos elegíveis, de ambos os gêneros, após uma triagem inicial e uma avaliação com neurologistas, foram randomizados (1:1) e separados no Grupo A e B e preencheram o Questionário de Avaliação da Incapacidade por Enxaqueca (MIDAS), o 12 – Item Allodynia Symptom Checklist (ASC – 12) – Versão Brasileira, e o Diário de Dor (durante um mês). Os resultados da caracterização da amostra mostraram maior ocorrência da migrânea nas mulheres, com homogeneidade em relação à idade, peso, altura, tempo de ocorrência, frequência e intensidade de dor entre os grupos. A náusea, fotofobia, fonofobia e osmofobia foram os fatores predisponentes mais evidentes nas análises realizadas. O MIDAS indicou presença de grau moderado de dor de cabeça em ambos os grupos e o ASC-12 do grupo A indicou presença de alodínia severa e no B, alodínia moderada. Esses dados indicam que a migrânea gera sérios problemas aos seus portadores, os quais interferem consideravelmente na sua qualidade de vida.
- 29 November 2019
- Published by Wiley in Pain Practice
- Vol. 20 (4) , 371-386
Low‐Intensity Photobiomodulation Decreases Neuropathic Pain in Paw Ischemia‐Reperfusion and Spared Nervus Ischiadicus Injury Experimental Models
Background: There is a wide range of animal models available today for studying chronic pain associated with a variety of etiologies and an extensive list of clinical manifestations of peripheral neuropathies. Photobiomodulation is a new tool for the treatment of pain in a convenient, noninvasive way.Objective: The aim of this work is to elucidate the effects of infrared light‐emitting diodes (LEDs) on behavioral responses to nociceptive stimuli in chronic pain models.Methods: Forty‐eight Swiss male mice weighing 25 to 35 g were used. Two chronic pain models, ischemia‐reperfusion (IR) and spared spinal nerve injury, were performed and then treated with infrared LED irradiation (390 mW, 890 nm, 17.3 mW/cm2, 20.8 J/cm2, for 20 minutes). The behavioral tests used were a mechanical hypersensitivity test von Frey test) and a cold allodynia test (acetone test).Results: The results showed that, in the IR model, the infrared LED had a significant effect on mechanical stimulation and cold allodynia on every day of treatment. In the spared nerve injury model, an analgesic effect was observed on every treatment day (when started on the 3rd and 7th days after the surgery). In both models, the effect was abolished when the treatment was interrupted.Conclusions: These findings suggest that photobiomodulation therapy may be a useful adjunct treatment for chronic pain.
- 29 November 2019
- Published by Wiley in Pain Practice
- Vol. 20 (4) , 371-386
Low‐Intensity Photobiomodulation Decreases Neuropathic Pain in Paw Ischemia‐Reperfusion and Spared Nervus Ischiadicus Injury Experimental Models
Background: There is a wide range of animal models available today for studying chronic pain associated with a variety of etiologies and an extensive list of clinical manifestations of peripheral neuropathies. Photobiomodulation is a new tool for the treatment of pain in a convenient, noninvasive way.Objective: The aim of this work is to elucidate the effects of infrared light‐emitting diodes (LEDs) on behavioral responses to nociceptive stimuli in chronic pain models.Methods: Forty‐eight Swiss male mice weighing 25 to 35 g were used. Two chronic pain models, ischemia‐reperfusion (IR) and spared spinal nerve injury, were performed and then treated with infrared LED irradiation (390 mW, 890 nm, 17.3 mW/cm2, 20.8 J/cm2, for 20 minutes). The behavioral tests used were a mechanical hypersensitivity test von Frey test) and a cold allodynia test (acetone test).Results: The results showed that, in the IR model, the infrared LED had a significant effect on mechanical stimulation and cold allodynia on every day of treatment. In the spared nerve injury model, an analgesic effect was observed on every treatment day (when started on the 3rd and 7th days after the surgery). In both models, the effect was abolished when the treatment was interrupted.Conclusions: These findings suggest that photobiomodulation therapy may be a useful adjunct treatment for chronic pain.
- 1 July 2019
- Published by Elsevier in Journal of Photochemistry and Photobiology B: Biology
- Vol. 196, 111513
Photobiomodulation therapy reduces acute pain and inflammation in mice
- 1 July 2019
- Published by Elsevier in Journal of Photochemistry and Photobiology B: Biology
- Vol. 196, 111513
Photobiomodulation therapy reduces acute pain and inflammation in mice